Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
EyePoint Pharmaceuticals is a commercial-stage ophthalmic pharmaceutical company focused on sustained-release drug delivery systems for treating eye diseases. The company's lead commercial product YUTIQ (fluocinolone acetonide intravitreal implant) treats chronic non-infectious uveitis affecting the posterior segment, while DEXYCU (dexamethasone intraocular suspension) addresses post-surgical ocular inflammation. EyePoint's proprietary Durasert technology platform enables extended drug release directly into the eye, reducing treatment burden compared to frequent injections.
EyePoint generates revenue through direct commercialization of YUTIQ to retina specialists and uveitis treatment centers, leveraging a specialized sales force targeting approximately 2,500 high-prescribing ophthalmologists in the US. The company's sustained-release implants command premium pricing due to reduced treatment frequency (YUTIQ lasts up to 36 months versus monthly injections for corticosteroids). Gross margins exceed 90% reflecting low manufacturing costs relative to pricing power in specialty ophthalmology. The business model depends on securing reimbursement from Medicare Part B and commercial payers, building key opinion leader advocacy, and expanding label indications. Pipeline value derives from applying Durasert technology to additional ophthalmic conditions, potentially generating upfront payments, development milestones, and royalties from partners.
YUTIQ quarterly prescription volume trends and market share gains in posterior uveitis treatment (tracked via Symphony Health data)
Clinical trial readouts for pipeline programs, particularly DURAVYU Phase 3 data for diabetic macular edema
FDA regulatory decisions on label expansions or new product approvals from Durasert platform
Partnership announcements or licensing deals that validate technology platform and provide non-dilutive funding
Cash runway updates and financing activities given negative operating cash flow requiring capital raises
Competitive threat from anti-VEGF therapies and corticosteroid alternatives with established efficacy data and broader label indications in retinal diseases, potentially limiting YUTIQ addressable market
Reimbursement pressure from payers scrutinizing high-cost specialty pharmaceuticals, particularly for sustained-release formulations where cost-effectiveness versus generic alternatives faces increasing scrutiny
Regulatory pathway complexity for ophthalmic implants requiring surgical administration, with FDA safety monitoring and potential label restrictions limiting commercial uptake
Allergan (AbbVie) and other large ophthalmology players developing competing sustained-release platforms with greater commercial infrastructure and KOL relationships
Generic corticosteroid injections offering significantly lower cost alternative despite inferior convenience profile, particularly in price-sensitive segments
Negative operating cash flow of $100M annually with current burn rate requiring additional capital raises within 12-18 months based on existing cash position, creating dilution risk for equity holders
Pre-revenue pipeline assets require substantial additional R&D investment with binary clinical trial outcomes, where negative data could eliminate future value and accelerate cash needs
low - Ophthalmic treatments for chronic conditions like uveitis are medically necessary and non-discretionary. Demand is driven by disease prevalence and diagnosis rates rather than economic cycles. However, elective procedures using DEXYCU (cataract surgery volumes) show modest sensitivity to consumer confidence and discretionary healthcare spending. Medicare and commercial insurance reimbursement insulates revenue from direct consumer economic pressure.
Rising interest rates create moderate headwinds through two channels: (1) Higher discount rates compress valuation multiples for pre-profitable biotech companies with cash flows years in the future, disproportionately impacting growth-stage names. (2) Increased financing costs for future capital raises, though current debt levels are minimal (0.11 D/E ratio). The 7.18 current ratio and existing cash provide near-term buffer, but eventual need for additional capital makes cost of financing relevant. Rate increases also strengthen the dollar, which has minimal impact given purely domestic revenue base.
Minimal direct credit exposure. The company does not extend significant customer credit as sales flow through specialty distributors with established payment terms. Balance sheet shows strong liquidity with current ratio above 7x, indicating no near-term refinancing risk. Credit market conditions affect ability to raise debt capital if needed, but equity markets are primary funding source for biotech at this stage.
growth - The 128% one-year return and 34% six-month return reflect momentum-driven speculation on clinical pipeline potential and commercial inflection. Pre-profitability with negative margins attracts risk-tolerant growth investors betting on technology platform validation and future revenue scaling. The stock appeals to biotech specialists focused on binary catalysts (FDA approvals, trial data) rather than value investors seeking current cash flows. High P/S ratio of 29x indicates market pricing in substantial future revenue growth from pipeline success.
high - Small-cap biotech with $1.2B market cap and binary clinical/regulatory catalysts exhibits significant volatility. Stock moves 10-20% on clinical data releases, partnership announcements, or financing events. Limited institutional ownership and low trading liquidity amplify price swings. Negative cash flow and periodic capital raises create dilution events that pressure shares. Estimated beta above 1.5 relative to broader market.
